U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Gartlehner G, Jonas DE, Morgan LC, et al. Drug Class Review: Constipation Drugs: Final Report [Internet]. Portland (OR): Oregon Health & Science University; 2007 Sep.

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Drug Class Review: Constipation Drugs

Drug Class Review: Constipation Drugs: Final Report [Internet].

Show details

References

1.
American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(Suppl 1):S1–4.
2.
Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004 Apr;99(4):750–9. [PubMed: 15089911]
3.
Johanson JF, Sonnenberg A, Koch TR. Clinical epidemiology of chronic constipation. J Clin Gastroenterol. 1989 Oct;11(5):525–36. [PubMed: 2551954]
4.
Stewart WF, Liberman JN, Sandler RS, Woods MS, Stemhagen A, Chee E. et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol. 1999 Dec;94(12):3530–40. [PubMed: 10606315]
5.
Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. The health-related quality of life and economic burden of constipation. PharmacoEconomics. 2005;23(5):461–76. [PubMed: 15896098]
6.
Rantis PC Jr., Vernava AM, 3rd, Daniel GL, Longo WE. Chronic constipation--is the work-up worth the cost? Dis Colon Rectum. 1997 Mar;40(3):280–6. [PubMed: 9118741]
7.
Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002 Dec;123(6):2108–31. [PubMed: 12454866]
8.
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. In: Drossman DA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, et al., eds. Rome III: The Functional Gastrointestinal Disorders, 3rd edition. McLean, VA: Degnon Associates, Inc. 2006.
9.
Ringel Y, Drossman DA. Irritable bowel syndrome: classification and conceptualization. J Clin Gastroenterol. 2002 Jul;35(1 Suppl):S7–10. [PubMed: 12184143]
10.
Locke GR, 3rd, Pemberton JH, Phillips SF. AGA technical review on constipation. American Gastroenterological Association. Gastroenterology. 2000 Dec;119(6):1766–78. [PubMed: 11113099]
11.
Locke GR, 3rd, Pemberton JH, Phillips SF. American Gastroenterological Association Medical Position Statement: guidelines on constipation. Gastroenterology. 2000 Dec;119(6):1761–6. [PubMed: 11113098]
12.
FDA. Public Health Advisory: Tegaserod maleate (marketed as Zelnorm). http://www​.fda.gov/cder​/drug/advisory/tegaserod.htm.2007.
13.
Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM. et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001 Apr;20(3 Suppl):21–35.
14.
Anonymous. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. CRD Report Number 4 (2nd edition). 2001 2001.
15.
Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. A simple and valid tool distinguished efficacy from effectiveness studies. J of Clinical Epidemiology. 2006 [PubMed: 16980143]
16.
Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F. et al. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7(27):iii-x, 1–173. [PubMed: 14499048]
17.
Egger M, Smith GD, Altman DG. Systematic Reviews in Health Care (2nd edition). 2001 2001.
18.
Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S. et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004 Dec 22;4(1):38. [PMC free article: PMC545647] [PubMed: 15615589]
19.
Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B. et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest. 2006 Jan;129(1):174–81. [PubMed: 16424429]
20.
Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III patient assessments of the effects of lubiprostone, a chloride channel-2 (CIC-2) activator, for the treatment of constipation [Abstract 899] Am J Gastroenterol. 2005;100(Supplement 9):S329–S30.
21.
Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Multicenter open-label study of oral lubiprostone for the treatment of chronic constipation. Am J Gastroenterol. 2005;100(Supplement 9):S331.
22.
Johanson JF, Panas R, Holland PC, Ueno R. Long-term efficacy of lubiprostone for the treatment of chronic constipation [Abstract M1171] Gastronenterology. 2006;130(Supplement 2):A-317.
23.
Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III study of lubiprostone, a chloride channel-2 (CIC-2) activator for the treatment of constipation: safety and primary efficacy [Abstract 896] Am J Gastroenterol. 2005;100(Supplement 9):S328–9.
24.
Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Multicenter open-label study of oral lubiprostone for the treatment of chronic constipation [Abstract 903] Am J Gastroenterol. 2005;100(Supplement 9):S331.
25.
Ueno R, Wahle A, Panas R, Joswick TR, Rivera E. Evaluation of safety and efficacy in a twelve-month study of lubiprostone for the treatment of chronic idiopathic constipation [Abstract 1269] Am J Gastroenterol. 2006;101(Supplement 2):S491.
26.
Ueno R, Joswick TR, Wahle A, Zhu Y, Holland PC. Efficacy and safety of lubiprostone for the treatment of chronic constipation in elderly vs. non-elderly subjects [Abstract S1262] Gastroenterology. 2006;130(4, Supplement 2):A-189.
27.
Ueno R, Panas R, Wahle A, Zhu Y, Holland PC. Long-term safety and efficacy of lubiprostone for the treatment of chronic constipation in elderly subjects [Abstract S1260] Gastroenterology. 2006;130(Supplement 2):A-188.
28.
Ueno R, Joswick TR, Wahle A, Zhu Y, Holland PC. Efficacy and safety of lubiprostone for the treatment of chronic constipation in male vs. female subjects [Abstract M1195] Gastroenterology. 2006;130(4, Supplement 2):A322.
29.
Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III efficacy and safety of lubiprostone, a novel chloride channel activator, for the treatment of constipation. Presentation at: World Congress of Gastroenterology. [Abstract R.0662]. 2005.
30.
Ueno R, Osama H, Engelke KJ. Effects of lubiprostone on morphine-induced constipation and analgesia [Abstract M1810] Gastroenterology. 2006;130(Suppl 2):A373–A4.
31.
DiPalma JA, DeRidder PH, Orlando RC, Kolts BE, Cleveland MB. A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative. Am J Gastroenterol. 2000 Feb;95(2):446–50. [PubMed: 10685748]
32.
Andorsky RI, Goldner F. Colonic lavage solution (polyethylene glycol electrolyte lavage solution) as a treatment for chronic constipation: a double-blind, placebo-controlled study. Am J Gastroenterol. 1990 Mar;85(3):261–5. [PubMed: 2178398]
33.
Cleveland MV, Flavin DP, Ruben RA, Epstein RM, Clark GE. New polyethylene glycol laxative for treatment of constipation in adults: a randomized, double-blind, placebo-controlled study. South Med J. 2001 May;94(5):478–81. [PubMed: 11372795]
34.
Tran LC, Di Palma JA. Lack of lasting effectiveness of PEG 3350 laxative treatment of constipation. J Clin Gastroenterol. 2005 Aug;39(7):600–2. [PubMed: 16000928]
35.
Fenn GC, Wilkinson PD, Lee CE, Akbar FA. A general practice study of the efficacy of Regulan in functional constipation. Br J Clin Pract. 1986 May;40(5):192–7. [PubMed: 3530306]
36.
Ashraf W, Park F, Lof J, Quigley EM. Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther. 1995 Dec;9(6):639–47. [PubMed: 8824651]
37.
Johanson JF, Wald A, Tougas G, Chey WD, Novick JS, Lembo AJ. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2004. pp. 796–805. [PubMed: 15354280]
38.
Kamm MA, Muller-Lissner S, Talley NJ, Tack J, Boeckxstaens G, Minushkin ON. et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol. 2005 Feb;100(2):362–72. [PubMed: 15667494]
39.
Lin SR, Ke MY, Luo JY, Yuan YZ, Wang JY, diTommaso S. et al. A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation. World J Gastroenterol. 2007 Feb 7;13(5):732–9. [PMC free article: PMC4066006] [PubMed: 17278196]
40.
Quigley EM, Wald A, Fidelholtz J, Boivin M, Pecher E, Earnest D. Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies. Clin Gastroenterol Hepatol. 2006 May;4(5):605–13. [PubMed: 16678076]
41.
Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. Mov Disord. 2006 Jan;21(1):115–6. [PubMed: 16142776]
42.
McRorie JW, Daggy BP, Morel JG, Diersing PS, Miner PB, Robinson M. Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther. 1998 May;12(5):491–7. [PubMed: 9663731]
43.
Attar A, Lemann M, Ferguson A, Halphen M, Boutron MC, Flourie B. et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut. 1999 Feb;44(2):226–30. [PMC free article: PMC1727381] [PubMed: 9895382]
44.
Wang HJ, Liang XM, Yu ZL, Zhou LY, Lin SR, Geraint M. A Randomised, Controlled Comparison of Low-Dose Polyethylene Glycol 3350 plus Electrolytes with Ispaghula Husk in the Treatment of Adults with Chronic Functional Constipation. Clinical Drug Investigation. 2004;24(10):569–76. [PubMed: 17523718]
45.
Wang HJ, Liang XM, Yu ZL, Zhou LY, Geraint M. A randomised, controlled comparison of low-dose polyethylene glycol 3350 plus electrolytes with ispaghula husk in the treatment of adults with chronic functional constipation. Drugs R D. 2005;6(4):221–5. [PubMed: 15991881]
46.
Voskuijl W, de Lorijn F, Verwijs W, Hogeman P, Heijmans J, Makel W. et al. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial. Gut. 2004 Nov;53(11):1590–4. [PMC free article: PMC1774276] [PubMed: 15479678]
47.
Nyhlin H, Bang C, Elsborg L, Silvennoinen J, Holme I, Ruegg P. et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol. 2004 Feb;39(2):119–26. [PubMed: 15000272]
48.
Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H. et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut. 2003;52(5):671–6. [PMC free article: PMC1773630] [PubMed: 12692051]
49.
Muller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B. et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001 Oct;15(10):1655–66. [PubMed: 11564007]
50.
Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G. et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2002 Nov;16(11):1877–88. [PubMed: 12390096]
51.
Tack J, Muller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A. et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut. 2005 Dec;54(12):1707–13. [PMC free article: PMC1774790] [PubMed: 16020489]
52.
Johanson JF, Panas R, Holland PC, Ueno R. A dose-ranging, double-blind, placebo-controlled study of lubiprostone in subjects with irritable bowel syndrome and constipation (c-ibs) [Abstract 131] Gastroenterology. 2006;130(Supplement 2):A-25.
53.
Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2006 Jan 1;23(1):191–6. [PubMed: 16393297]
54.
Johanson JF, Gargano MA, Patchen ML, Ueno R. Efficacy and safety of a novel compound,RU-0211, for the treatment of constipation [Abstract M1511] Gastroenterology. 2002;122(Supplement 4):A-315.
55.
Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation [Abstract 372] Gastroenterology. 2003;124(Supplement 1):A-48.
56.
Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation [Abstract 749] Gastroenterology. 2004;126(4, Supplement 2):A-100.
57.
FDA Center for Drug Evaluation and Research. Medical Review NDA 21–908 of RU-0211 (lubiprostone). http://www​.fda.gov/cder​/foi/nda/2006/021908s000​_Amitiza_MEDR.pdf.2006.
58.
Ashraf W, Park F, Lof J, Quigley EM. An examination of the reliability of reported stool frequency in the diagnosis of idiopathic constipation. Am J Gastroenterol. 1996 Jan;91(1):26–32. [PubMed: 8561138]
59.
Fried M, Johanson JF, Gwee KA, Wagner A, Pecher E, Rueegg P. Efficacy of tegaserod in chronic constipation in men. Am J Gastroenterol. 2007 Feb;102(2):362–70. [PubMed: 17156137]
60.
Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2004;(1):CD003960. [PubMed: 14974049]
61.
Morganroth J, Rüegg PC, Dunger-Baldauf C, Appel-Dingemanse S, Bliesath H, Lefkowitz M. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. The American journal of gastroenterology. 2002;97(9):2321–7. [PubMed: 12358251]
62.
Fried M, Beglinger C, Bobalj NG, Minor N, Coello N, Michetti P. Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2005 Apr;17(4):421–7. [PubMed: 15756094]
63.
Tougas G, Snape WJ Jr., Otten MH, Earnest DL, Langaker KE, Pruitt RE. et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2002 Oct;16(10):1701–8. [PubMed: 12269961]
64.
Muller-Lissner S, Kamm MA, Musoglu A, Earnest DL, Dunger-Baldauf C, Shetzline MA. Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation. Am J Gastroenterol. 2006 Nov;101(11):2558–69. quiz 671. [PubMed: 17090282]
65.
Dettmar PW, Sykes J. A multi-centre, general practice comparison of ispaghula husk with lactulose and other laxatives in the treatment of simple constipation. Curr Med Res Opin. 1998;14(4):227–33. [PubMed: 9891195]
66.
Rouse M, Chapman N, Mahapatra M, Grillage M, Atkinson SN, Prescott P. An open, randomised, parallel group study of lactulose versus ispaghula in the treatment of chronic constipation in adults. Br J Clin Pract. 1991 Spring;45(1):28–30. [PubMed: 1931536]
67.
Pashankar DS, Loening-Baucke V, Bishop WP. Safety of polyethylene glycol 3350 for the treatment of chronic constipation in children. Arch Pediatr Adolesc Med. 2003 Jul;157(7):661–4. [PubMed: 12860787]
68.
Loening-Baucke V, Krishna R, Pashankar DS. Polyethylene glycol 3350 without electrolytes for the treatment of functional constipation in infants and toddlers. J Pediatr Gastroenterol Nutr. 2004 Nov;39(5):536–9. [PubMed: 15572895]
69.
Youssef NN, Peters JM, Henderson W, Shultz-Peters S, Lockhart DK, Di Lorenzo C. Dose response of PEG 3350 for the treatment of childhood fecal impaction. J Pediatr. 2002 Sep;141(3):410–4. [PubMed: 12219064]
70.
van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. Am J Gastroenterol. 2006 Oct;101(10):2401–9. [PubMed: 17032205]
71.
Cash BD, Lacy BE. Systematic review: FDA-approved prescription medications for adults with constipation. Gastroenterology and Hepatology. 2006;2(10):736–49. [PMC free article: PMC5358085] [PubMed: 28325992]
72.
Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Initial and sustained effects of lubiprostone, a chloride channel-2 (CIC-2) activator for the treatment of constipation: data from a 4-week phase III study [Abstract 884] Am J Gastroenterol. 2005;100(Suppement 9):S324–S5.
73.
Haycox A, Howard S, Partridge A, Wright T. Comparison of evidence and practice in the treatment of constipation. J Med Econ. 2001;4:91–8.
74.
Jones MP, Talley NJ, Nuyts G, Dubois D. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci. 2002 Oct;47(10):2222–30. [PubMed: 12395895]
75.
Tramonte SM, Brand MB, Mulrow CD, Amato MG, O'Keefe ME, Ramirez G. The treatment of chronic constipation in adults. A systematic review. J Gen Intern Med. 1997 Jan;12(1):15–24. [PMC free article: PMC1497052] [PubMed: 9034942]
76.
Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007 Jun 1;25(11):1351–61. [PubMed: 17509103]
77.
Michail S, Gendy E, Preud'Homme D, Mezoff A. Polyethylene glycol for constipation in children younger than eighteen months old. J Pediatr Gastroenterol Nutr. 2004 Aug;39(2):197–9. [PubMed: 15269628]
Copyright © 2007, Oregon Health & Science University, Portland, Oregon.
Bookshelf ID: NBK10498
Contents

Views

Other titles in this collection

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...